Trials / Completed
CompletedNCT04773431
Safety Evaluation of LSCD101 Transplantation for Limbal Stem Cell Deficiency
Phase I Study to Evaluate Safety of LSCD101(Cultured Autologous Limbal Epithelial Cell Sheet) Transplantation for Limbal Stem Cell Deficiency
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- CliPS Co., Ltd · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Clinical Study Objective: To evaluate the tolerability and safety after transplantation of LSCD101 in patients with intractable limbal stem cell deficiency Study Method: Subjects who finally meet the inclusion/exclusion criteria results of the subject eligibility evaluation will receive transplantation of the investigational product. Adverse drug reaction will be confirmed during 24 weeks after transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation | LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) is transplanted in the lesion. |
Timeline
- Start date
- 2020-01-31
- Primary completion
- 2021-01-14
- Completion
- 2021-01-14
- First posted
- 2021-02-26
- Last updated
- 2021-02-26
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04773431. Inclusion in this directory is not an endorsement.